Comparative study of the analgesic effect of Naproff and paracetamol in combination with chondroprotectors in the treatment of osteoarthritis

Author: O.A. Radomsky, National Medical Academy of Postgraduate Education. P.L. Shupika


Summary

The aim of the aftermarketing investigation was to study analgesic efficacy of combined therapy with Naproff (naproxen sodium) and complex Protecta in the treatment of patients with osteoarthritis of the knee and hip. In the study group (45 patients) the conservative treatment with Naproff and chondroprotector Protecta were used. In the control group (45 patients) were administered paracetamol and complex Protecta. Treatment continued for 3 months. Found that the combined use of the drug Naproff and Protecta provides significantly better analgesic therapy in patients with osteoarthritis of the hip and knee joints in cases of severe to moderate pain. At the same time the use of paracetamol in combination with the Protecta is sufficiently effective only in patients with moderate pain and ineffective in patients with severe pain. In general, the positive results obtained in analgesic therapy 75,5% of cases the main group and 46,6% of control (p<0,05).

Key words: Deforming osteoarthritis, knee and hip joints, complex treatment, Naproff, Protekta.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design